DTIL · XBRL financial data

Precision Biosciences financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (DTIL's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	24,285	115,529	25,098	48,727	68,696	34,264
Research and development	98,061	115,238	83,939	53,375	59,559	54,172
General and administrative	36,052	39,693	41,525	39,088	35,299	32,240
Total operating expenses	134,113	154,931	125,464	92,463	94,858	86,412
Operating income (loss)	(109,828)	(39,402)	(100,366)	(43,736)	(26,162)	(52,148)
Interest income	822	208	—	—	—	—
Interest expense	—	132	1,111	2,230	1,782	1,422
Other income (expense)	822	8,800	(11,271)	1,209	33,329	5,539
Income tax expense (benefit)	23	—	—	—	0	0
Net income (loss)	(109,006)	(30,602)	(111,637)	(61,319)	7,167	(45,724)
Earnings per share, basic‡ USD per share	—	(15.60)	(38.10)	(478.80)	1.05	(3.56)
Earnings per share, diluted‡ USD per share	—	(15.60)	(38.10)	(478.80)	1.04	(3.56)
Weighted average shares, basic‡ thousands of shares	—	1,956	2,930	128	6,833	12,826
Weighted average shares, diluted‡ thousands of shares	—	1,956	2,930	128	6,884	12,826

‡ Per-share figures and share counts are adjusted for the 1-for-30 stock split (February 2024); filings made before it reported them unadjusted.
† Share count changed about 1/16 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 45x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (DTIL's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	89,798	143,663	189,576	116,678	85,899	110,823
Marketable securities	—	—	—	—	413	4,762
Accounts receivable	10,000	488	720	901	229	0
Total current assets	105,564	161,754	199,105	136,359	94,989	118,740
Property and equipment, net	35,090	25,154	20,190	6,338	3,089	1,425
Right-of-use asset	6,410	4,180	2,974	8,263	7,090	5,805
Total assets	150,158	211,498	238,169	159,781	136,388	154,416
Accounts payable	792	1,144	1,225	2,968	1,312	296
Total current liabilities	42,829	35,980	59,664	49,987	14,980	8,913
Lease liability, non-current	8,586	4,813	2,776	7,723	6,404	4,897
Total liabilities	105,733	120,330	177,736	140,920	79,995	62,168
Accumulated deficit	(286,073)	(316,675)	(428,312)	(489,631)	(482,464)	(528,188)
Total stockholders' equity	44,425	91,168	60,433	18,861	56,393	92,248
Total liabilities and equity	150,158	211,498	238,169	159,781	136,388	154,416
Common shares outstanding (cover page)‡ thousands of shares	1,900	2,035	3,710	231	10,482	24,727

‡ Per-share figures and share counts are adjusted for the 1-for-30 stock split (February 2024); filings made before it reported them unadjusted.
† Share count changed about 1/16 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 45x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (DTIL's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(109,006)	(30,602)	(111,637)	(61,319)	7,167	(45,724)
Stock-based compensation	13,786	16,514	19,197	14,040	12,604	10,186
Net cash from operating activities	(87,386)	(10,853)	(45,753)	(84,114)	(58,445)	(65,843)
Net cash from investing activities	(5,031)	(5,803)	(3,319)	5,829	(215)	(634)
Proceeds from issuing common stock	—	25,477	49,345	4,986	—	—
Repayments of long-term debt	—	2,500	—	—	—	—
Net cash from financing activities	1,329	70,521	94,985	5,387	50,450	95,162
Net change in cash	(91,088)	53,865	45,913	(72,898)	(8,210)	28,685

† Share count changed about 1/16 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 45x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Precision Biosciences	81,698	0	(15,132)*	27.9M	6.1 quarters	Q3 FY26 10-QSep 30, 2026
Opus Genetics	88,812	755	(11,950)*	83.2M	7.4 quarters	Q2 FY26 10-QJun 30, 2026
Acumen Pharmaceuticals	53,075	not reported	(26,653)*	72.3M	3.4 quarters	Q3 FY26 10-QSep 30, 2026
Immucell	8,860	7,186	3,019*	9.1M	—	Q2 FY26 10-QJun 30, 2026
Fortress Biotech	196,576	18,718	(59,277)*	33.3M	3.3 quarters	Q2 FY26 10-QJun 30, 2026
Fitlife Brands	1,089	not reported	3,635*	9.4M	—	Q2 FY26 10-QJun 30, 2026
Actinium Pharmaceuticals	36,473	35,000	(5,179)*	31.4M	7.0 quarters	Q2 FY26 10-QJun 30, 2026
Lite Strategy	5,706	not reported	(1,164)*	30.4M	4.9 quarters	Q4 FY26 10-KJun 30, 2026
Cue Biopharma	17,392	7,877	(29,004)*	7.3M	0.6 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.